NEW YORK--(BUSINESS WIRE)--CB Pharma Acquisition Corp. (“CB Pharma”) (NASDAQ:CNLM; CNLMU; CNLMR; CNLMW) announced today that it held its extraordinary general meeting of shareholders and that at such ...
HOUSTON and THE WOODLANDS, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- McDermott International, Inc. (“McDermott”) (NYSE:MDR) and CB&I (NYSE:CBI) today announced both companies have received the necessary ...
Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it ...
HOUSTON, May 10, 2018 (GLOBE NEWSWIRE) -- McDermott International, Inc. (“McDermott” or the “Company”) (NYSE:MDR) today announced that it has completed its combination with Chicago Bridge & Iron ...
Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma. Background: IDH mutant astrocytomas express high levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results